布基纳法索多价脑膜炎球菌疫苗替代接种策略的成本效果:传播动力学模型研究
该研究用传播动力学模型评估布基纳法索现行A群结合疫苗加反应性接种策略与三种多价疫苗替代策略的健康影响和成本。30年模拟显示,含1–29岁全国补种并纳入EPI的Prevention 2可大幅减少脑膜炎病例,且在疫苗价格4美元/剂时具有成本效果。
要点
- Prevention 2在无血清群替换时减少78%病例,完全替换时减少87%。
- PMC疫苗价格4美元/剂时,若发生菌株替换,PMC策略可节省成本。
- 无替换时,Base Prime、Prevention 1和2每避免1个DALY成本分别为51、188和246美元。
核心结论
- 含1–29岁全国补种并纳入EPI的多价结合疫苗策略具有成本效果,可避免大量脑膜炎病例。
研究设计与样本
- 研究开发并校准了脑膜炎球菌传播的数学模型,模拟布基纳法索现行Base策略与三种替代策略30年的DALY和成本。
主要发现
- 30年模拟中,Prevention 2在无血清群替换时避免78%病例(95%预测区间63%-90%),完全替换时避免87%(77%-93%)。
- PMC疫苗价格4美元/剂时,若发生菌株替换,Base Prime、Prevention 1和2均预期节省成本。
- 若无菌株替换,Base Prime、Prevention 1和2每避免1个DALY的成本分别为51美元(-236, 490)、188美元(-97, 626)和246美元(-53, 703)。
临床怎么用
- 结果提示,将多价结合疫苗纳入EPI并联合1–29岁全国补种,在当前WHO推荐的反应性接种策略基础上可具成本效果。
局限性
- 研究假设所有循环脑膜炎球菌血清群可聚为单一群体,若疫苗效果在血清群间差异显著或存在复杂血清群间交互,模型见解会受限。
- 分析仅限布基纳法索,并假设多价疫苗对所有血清群提供同等保护,需进一步研究评估该假设的稳健性及其他脑膜炎带国家的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The introduction of a conjugate vaccine for serogroup A Neisseria meningitidis has dramatically reduced disease in the African meningitis belt. In this context, important questions remain about the performance of different vaccine policies that target remaining serogroups. Here, we estimate the health impact and cost associated with several alternative vaccination policies in Burkina Faso. METHODS AND FINDINGS: We developed and calibrated a mathematical model of meningococcal transmission to project the disability-adjusted life years (DALYs) averted and costs associated with the current Base policy (serogroup A conjugate vaccination at 9 months, as part of the Expanded Program on Immunization [EPI], plus district-specific reactive vaccination campaigns using polyvalent meningococcal polysaccharide [PMP] vaccine in response to outbreaks) and three alternative policies: (1) Base Prime: novel polyvalent meningococcal conjugate (PMC) vaccine replaces the serogroup A conjugate in EPI and is also used in reactive campaigns; (2) Prevention 1: PMC used in EPI and in a nationwide catch-up campaign for 1-18-year-olds; and (3) Prevention 2: Prevention 1, except the nationwide campaign includes individuals up to 29 years old. Over a 30-year simulation period, Prevention 2 would avert 78% of the meningococcal cases (95% prediction interval: 63%-90%) expected under the Base policy if serogroup A is not replaced by remaining serogroups after elimination, and would avert 87% (77%-93%) of meningococcal cases if complete strain replacement occurs. Compared to the Base policy and at the PMC vaccine price of US$4 per dose, strategies that use PMC vaccine (i.e., Base Prime and Preventions 1 and 2) are expected to be cost saving if strain replacement occurs, and would cost US$51 (-US$236, US$490), US$188 (-US$97, US$626), and US$246 (-US$53, US$703) per DALY averted, respectively, if strain replacement does not occur. An important potential limitation of our study is the simplifying assumption that all circulating meningococcal serogroups can be aggregated into a single group; while this assumption is critical for model tractability, it would compromise the insights derived from our model if the effectiveness of the vaccine differs markedly between serogroups or if there are complex between-serogroup interactions that influence the frequency and magnitude of future meningitis epidemics. CONCLUSIONS: Our results suggest that a vaccination strategy that includes a catch-up nationwide immunization campaign in young adults with a PMC vaccine and the addition of this new vaccine into EPI is cost-effective and would avert a substantial portion of meningococcal cases expected under the current World Health Organization-recommended strategy of reactive vaccination. This analysis is limited to Burkina Faso and assumes that polyvalent vaccines offer equal protection against all meningococcal serogroups; further studies are needed to evaluate the robustness of this assumption and applicability for other countries in the meningitis belt.
引用
- Yaesoubi R, Trotter C, Colijn C, et al. The cost-effectiveness of alternative vaccination strategies for polyvalent meningococcal vaccines in Burkina Faso: A transmission dynamic modeling study. PLoS Med. 2018. PMID: 29364884. doi:10.1371/journal.pmed.1002495
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。